Copy
View this email in your browser

Issue 9 | September 2020

<<First Name>>, here is your latest newsletter from Cochrane Heart.

Co-Publications




 
Due to interest in our relevant and up-to-date content, we regularly co-publish our reviews in other journals. In August the open access journal 'Global Heart' published 'Mediterranean-Style Diet for the Primary and Secondary Prevention of Cardiovascular Disease: A Cochrane Review'.

Read the Cochrane review.

Revman 5.4 and Revman Web

Cochrane have made important changes to allow the two versions of RevMan - RevMan Web (online) and RevMan 5 (desktop) to work more closely together. These are important changes that will affect all authors.

A final version of RevMan 5 (RevMan 5.4) is now available for download. RevMan 5.4 looks and feels like RevMan 5.3 but will be more closely connected to RevMan Web.

Please download RevMan 5.4 now if you wish to continue to work on your Cochrane Reviews in desktop RevMan. Cochrane will be switching off RevMan 5.3 in mid-August and you will not be able to edit your reviews.


For further information on Revman 5.4 and Revman Web, visit the Cochrane Online Learning portal.

Cochrane Conflict of Interest Policy



Cochrane has recently announced an udpated and more rigorous conflict of interest policy with the anticipated launch on 1 October 2020. The updated policy will apply to all newly registered titles and updates that begin after the launch date, and will not apply to ongoing projects registered before the launch.
Please
read it here and contact us with any questions you may have.

Update: Cochrane have now produced a one page quick guidance for authors which explains the key points of the CoI policy for Cochrane Library Content.

Cochrane also have a COI training portal available here and a recorded webinar series available here.

Vacant titles

Interested in writing a Cochrane review and an expert in cardiology? - Consider these vacant titles:

Proposals closing on 31 December 2020 (deadline extended):
  • Remote monitoring of Implantable Cardiac Defibrillators for prevention of cardiovascular outcomes
  • Alcohol consumption and cardiovascular disease**

**After reviewing the scope of this title, we invite proposals for three narrower topics as follows:

Interventions for alcohol cessation in people with heart failure
Interventions for alcohol cessation in people with atrial fibrillation
Interventions for alcohol cessation in people with ischemic heart disease

  • Colchicine for the primary prevention of cardiovascular events (supersedes our existing review that is split into two new reviews, one for primary prevention and one for secondary prevention)
Details on how to submit your proposals are here. 

Publications

Recent protocol publications Recent review publictions Recent updated publications Upcoming protocols/reviews
  • Ivabradine as adjuvant treatment for chronic heart failure (review)
  • Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation (protocol)
  • Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis (protocol)
  • Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass (review)
  • Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases (protocol)
Please give us your feedback!
Twitter
Website






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Cochrane Heart Group · 222 Euston Road · London, Lnd EC4N 1 · United Kingdom

Email Marketing Powered by Mailchimp